More Than Manufacturing

As the pharmaceutical industry advances toward more patient-centric therapies, complex dosage forms are being shaped not only by formulation science but also by manufacturing innovation. Technologies that improve dosing flexibility, administration, and patient experience are becoming increasingly important.

Pharmaceutical 3D printing (3DP) has evolved into a proven platform for complex dosage forms. Aprecia’s first FDA-approved 3D printed medicine helped validate additive manufacturing as a commercial pharmaceutical technology. As regulators place greater emphasis on patient-centric drug development and real-world usability, 3DP is gaining attention for its ability to support innovative dosage forms, flexible dosing, and improved administration.

A New Era for Complex Dosage Forms

Historically, pharmaceutical manufacturing was considered the final step in bringing a drug to market: a means of scaling a successful formulation. Today, however, manufacturing is becoming part of the clinical and commercial strategy.

Pharmaceutical 3DP offers an alternative approach.

By building dosage forms layer by layer from digital designs, additive manufacturing enables a level of flexibility difficult to achieve with conventional tablet compression processes. Developers can create highly porous structures, tailor dosage strengths, modify tablet geometry, and potentially combine multiple medications into a single dosage form.

The result is a broader toolkit for designing medicines around patients rather than asking patients to adapt to manufacturing limitations.

Regulatory Momentum Continues to Grow

Recent regulatory developments suggest that additive manufacturing has moved from a niche innovation to a technology deserving serious consideration.

Earlier this year, the European Medicines Agency (EMA) released guidance focused specifically on implementing 3DP technology for solid oral dosage forms. The agency described additive manufacturing as an emerging technology with significant pharmaceutical potential, citing applications in patient-centric dosage forms, personalized medicine, flexible dosing, and customizable drug combinations.

Notably, the guidance focuses on patient usability, flexibility, and treatment personalization rather than manufacturing novelty alone.

Similarly, the U.S. Food and Drug Administration (FDA) continues to emphasize patient-focused drug development initiatives and advanced manufacturing technologies that support improved patient outcomes and product quality.

Together, these regulatory signals indicate growing recognition that dosage form design can play an important role in the overall effectiveness of a therapy.

While interest in pharmaceutical 3DP continues to expand, Aprecia remains one of the industry’s leading pioneers. Its proprietary ZipDose® technology demonstrated that additive manufacturing could create highly porous dosage forms capable of delivering high drug loads while rapidly disintegrating with a sip of liquid. The approval of the first FDA-approved 3D printed medicine showed that additive manufacturing could successfully transition from concept to commercial pharmaceutical product.

Putting Patients at the Center

Patient-centricity has become a driving force across pharmaceutical development. While much of the conversation has focused on clinical trials and patient engagement, dosage form design is emerging as a critical component of the patient experience.

Many patients face daily challenges with oral medications. Children and older adults may struggle to swallow conventional tablets. Caregivers often need to manipulate products for feeding tube administration. Patients undergoing dose titration may require multiple strengths, creating complexity and opportunities for dosing errors.

Additive manufacturing offers a different model, enabling dosage forms to be digitally tailored for specific strengths, structures, and administration needs with greater efficiency and flexibility.

The potential value of this approach was demonstrated by Spritam®, the first FDA-approved 3D printed drug product. Its highly porous structure enables rapid disintegration with a small amount of liquid, helping address administration challenges for certain patient populations. More importantly, it demonstrated that dosage form engineering itself can improve the patient experience.

Flexibility as a Competitive Advantage

Beyond patient benefits, pharmaceutical 3DP is changing how manufacturers think about product development and lifecycle management.

One of the technology’s most compelling advantages is its ability to produce multiple dosage strengths from a common formulation platform. Rather than requiring entirely separate manufacturing processes, dosage adjustments can be achieved through validated digital process parameters.

For therapies requiring individualized dosing, narrow therapeutic windows, or gradual titration schedules, this flexibility creates significant opportunities. It may also support more efficient development pathways and inventory management strategies.

The technology is also attracting interest in orphan and rare disease therapies, where smaller patient populations may benefit from more flexible manufacturing and batch-size requirements.

As personalized medicine continues to gain momentum, manufacturing flexibility is becoming increasingly valuable.

Looking Ahead

The future potential of pharmaceutical 3DP extends beyond individualized dosing. Interest continues to grow around combination therapies, including so-called “polypills” that incorporate multiple active ingredients within a single dosage form.

Such approaches could help simplify treatment regimens, reduce pill burden, and improve adherence for patients managing chronic conditions that require several medications.

At the same time, the technology aligns closely with broader industry initiatives including Quality by Design (QbD), digital manufacturing, real-time process monitoring, and advanced manufacturing frameworks supported by both the FDA and EMA.

While conventional manufacturing will remain essential for many products, additive manufacturing is expanding what complex dosage forms can achieve.

The broader significance of pharmaceutical 3DP is not simply that it offers a new way to manufacture medicines. It represents the convergence of several major industry trends: patient-centric drug development, personalized medicine, regulatory modernization, digital manufacturing, and growing demand for treatment flexibility.

As pharmaceutical companies search for ways to create value beyond the molecule itself, dosage form innovation is becoming an increasingly important differentiator.

For organizations developing the next generation of complex dosage forms, the question is no longer whether advanced manufacturing has a role in pharmaceutical development, but how best to leverage it to improve real-world treatment outcomes and address unmet patient needs.

Aprecia’s pioneering work in pharmaceutical 3D printing, including the development of the first FDA-approved 3D printed medicine, helped demonstrate that additive manufacturing could make the transition from innovative concept to commercial product. As the industry continues to embrace patient-centric drug development, personalized medicine, and more flexible manufacturing models, pharmaceutical 3D printing is increasingly being recognized not simply as a production technology, but as a platform for reimagining how medicines are designed, delivered, and experienced by patients.